New agents on the horizon in gastric cancer.

Lordick, F; Shitara, K; Janjigian, Y Y

Lordick, F; Shitara, K; Janjigian, Y Y.

Affiliation

Lordick F; University Cancer Center Leipzig, University Medicine Leipzig, Leipzig, Germany.
Shitara K; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
Janjigian YY; Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, USA.

Ann Oncol ; 28(8): 1767-1775, 2017 Aug 01.

Article in En | MEDLINE | ID: mdl-28184417

Subject(s)

Antineoplastic Agents, Immunological/therapeutic use; Stomach Neoplasms/drug therapy; Angiogenesis Inhibitors/therapeutic use; DNA Damage; DNA Repair; Humans; Immunotherapy; Neoplastic Stem Cells/drug effects; Stomach Neoplasms/genetics; Stomach Neoplasms/therapy; Tumor Microenvironment

Key words

Claudin 18.2; HER2; STAT3; gastric cancer; immunotherapy; stem cell inhibition

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stomach Neoplasms / Antineoplastic Agents, Immunological Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2017 Type: Article Affiliation country: Germany

Fulltext

XML

PubMed Links

Search on Google